Bakuchiol has been positioned as a “natural retinol alternative” since it entered mainstream skincare around 2018. That framing is partly accurate and partly misleading, and the nuance matters for how you use it. The research on bakuchiol has grown significantly, and what it now shows is interesting enough that the comparison with retinol deserves a careful look.
What bakuchiol is
Bakuchiol is a meroterpene phenol derived from the seeds and leaves of Psoralea corylifolia, a plant used in traditional Ayurvedic and Chinese medicine. It’s structurally completely different from retinol or any other retinoid. The “retinol alternative” framing is about functional effects, not chemical similarity.
The early research that generated excitement for bakuchiol in skincare found that it activated retinoid receptors on skin cells (specifically RAR and RXR receptors) and stimulated similar gene expression changes to those induced by retinol. If bakuchiol triggers the same cellular responses as retinol without being a retinoid, it might achieve retinoid-like benefits with the tolerability profile of a completely different compound.
The key clinical comparison study
The study most often cited is the 2019 randomised, double-blind, placebo-controlled trial published in the British Journal of Dermatology. In this 12-week study, participants applied either 0.5% bakuchiol twice daily or 0.5% retinol once daily to their face. The comparison was designed to use a potentially disadvantaging protocol for bakuchiol (twice daily versus retinol once daily) to give retinol a theoretical tolerability advantage.
The results: both groups showed equivalent improvements in fine lines and wrinkles, hyperpigmentation, skin firmness, and overall skin texture. Retinol caused more facial stinging and skin scaling than bakuchiol. The bakuchiol group had significantly fewer side effects.
This is a meaningful clinical result. Bakuchiol at 0.5% twice daily produced anti-aging effects comparable to retinol at 0.5% once daily with substantially better tolerability. A subsequent smaller study using 0.5% bakuchiol also found improvements in fine lines and photodamage at 12 weeks.
Where the comparison has limitations
The comparison was against 0.5% retinol, which is a mid-strength OTC formulation. Prescription tretinoin (all-trans retinoic acid) at concentrations like 0.025% or 0.05% has several decades of extensive clinical evidence, including randomised controlled trials, showing significant improvements in wrinkles, hyperpigmentation, and skin texture. The evidence base for tretinoin is substantially stronger than for bakuchiol.
There have been no published trials comparing bakuchiol directly to tretinoin. Whether bakuchiol would match tretinoin’s performance is unknown, and based on mechanistic differences, it’s unlikely. Tretinoin’s effects are well-characterised and include direct stimulation of collagen synthesis through fibroblast activation, acceleration of cell turnover that retinol achieves less potently. Bakuchiol’s mechanism of action, while involving retinoid receptor activation, may not replicate all of tretinoin’s pathway effects at the same magnitude.
The 12-week comparison is also a relatively short timeframe. Retinol typically produces better and better results over a year or more of consistent use as cumulative collagen stimulation builds. Longer-term comparisons between bakuchiol and retinol haven’t been published.
Bakuchiol’s actual advantages
The tolerability advantage is real and clinically significant. People who find retinol too irritating, who experience persistent redness, peeling, or sensitivity that doesn’t resolve after the typical adjustment period, have a genuine alternative in bakuchiol. The lower side effect profile isn’t just about comfort; it’s about adherence. A product people can use consistently produces better results than one they use sporadically because of side effects.
Bakuchiol is considered safe in pregnancy (no formal pregnancy safety studies exist, but it’s a plant phenol rather than a retinoid and is not teratogenic under current understanding). This makes it valuable for the significant gap in retinoid use that pregnancy creates.
It’s photostable, meaning it doesn’t degrade in sunlight and can be used in the morning as well as the evening. Retinoids, particularly retinol, degrade in UV and are conventionally evening-only products. Bakuchiol’s stability makes twice-daily use practical and potentially more effective than a once-daily retinol regime at equivalent concentrations.
It’s also anti-inflammatory, unlike retinoids. Many of retinol’s side effects (redness, irritation, sensitivity) come from its pro-inflammatory mechanism of action at the skin surface. Bakuchiol’s anti-inflammatory properties mean it supports skin barrier health while delivering anti-aging effects, making it particularly suitable for sensitive, eczema-prone, or reactive skin types.
Who should choose each
Retinol (or prescription tretinoin) remains the most evidence-backed option for people who can tolerate it. The decades of clinical evidence, the established mechanism of action, and the available prescription-strength options make it the stronger choice for people focused on maximising anti-aging efficacy and who can manage the tolerability challenges.
Bakuchiol is the better choice for people who can’t tolerate retinoids, who are pregnant or breastfeeding, who prefer morning application or twice-daily use, or who have sensitive or reactive skin where retinol’s inflammatory mechanism causes problems. It’s not a compromise; it’s a genuinely effective anti-aging ingredient that happens to suit a different skin profile.
For people who tolerate retinol well but want additional anti-aging activity, combining both is an option. They work through partly different pathways and are compatible, with some research suggesting the combination may be more effective than either alone. Using bakuchiol in the morning and retinol in the evening is a practical approach for this combination.